Oxcarbazepine Oral Suspension — Class II drug recall D-1863-2019
Terminated recall by West-Ward Columbus Inc, reported 2019-09-25, distributed nationwide. Failed Impurities/Degradation Specificattion
| Recall number | D-1863-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | West-Ward Columbus Inc, Columbus, OH, United States |
| Recall initiated | 2019-09-09 |
| Classified | 2019-09-16 |
| Reported by FDA | 2019-09-25 |
| Terminated | 2022-06-15 |
| Distributed | Nationwide (US) |
| Quantity | 32,347 bottles |
| Reason classes | specification failure |
| NDC | 00054-0199-59 |
| Lot numbers | AA3957A, AA3958A, AA5164A |
| Expiration dates | 2020-05-20, 2020-09-20 |
Product
Oxcarbazepine Oral Suspension, USP, 300 mg/5 mL, 250 mL per bottle, Rx Only, Distr. by: West-Ward Pharmaceuticals,Eatontown, NJ. NDC:0054-0199-59
Reason for recall
Failed Impurities/Degradation Specificattion
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1863-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.